In this study, we established a potent platform for tailored inflammation control via SORT LNP-based lung-targeted delivery of chemically modified sPD-L1 mRNA, which could be a promising strategy for ARDS treatment. This evidence concerns the gene SPDL1 and acute respiratory distress syndrome.